Literature DB >> 8842657

The effects of midazolam or propofol followed by suxamethonium on the QT interval in humans.

D G Michaloudis1, F S Kanakoudis, A M Petrou, A S Konstantinidou, B J Pollard.   

Abstract

Prolongation of the QT interval may produce potentially hazardous arrhythmias. The effects of midazolam or propofol, followed by suxamethonium on the QT interval have been investigated. Thirty patients, ASA I or II, without cardiovascular disease, electrolyte abnormalities or receiving any medication were studied. All patients were premedicated with midazolam 0.08 mg kg-1 i.m., 30-60 min prior to surgery. Anaesthesia was induced with either midazolam 0.4 mg kg-1 i.v., (15 patients) or propofol 1 mg kg-1 i.v. bolus, followed by a continuous infusion (15 patients). ECG, heart rate and arterial pressure were measured before induction of anaesthesia and at 1 and 3 min after the bolus of midazolam or propofol. Further recordings were obtained at 1 and 3 min after a bolus of suxamethonium 1.5 mg kg-1 i.v. and also immediately after tracheal intubation and 1 min later. Neither midazolam nor propofol had any significant effect on QTc interval. Prolongation of QTc was observed in both groups after suxamethonium and this was further prolonged following intubation. Heart rate and arterial pressure were also increased significantly in both groups following intubation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842657     DOI: 10.1046/j.1365-2346.1996.00022.x

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  14 in total

Review 1.  QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes.

Authors:  Alan David Kaye; Jacqueline Volpi-Abadie; J Michael Bensler; Adam M Kaye; James H Diaz
Journal:  J Anesth       Date:  2013-02-15       Impact factor: 2.078

Review 2.  Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.

Authors:  Fabrizio De Ponti; Elisabetta Poluzzi; Andrea Cavalli; Maurizio Recanatini; Nicola Montanaro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Case scenario: anesthesia-related cardiac arrest in a child with Timothy syndrome.

Authors:  Aruna T Nathan; Charles Antzelevitch; Lisa M Montenegro; Victoria L Vetter
Journal:  Anesthesiology       Date:  2012-11       Impact factor: 7.892

Review 4.  [Long QT syndrome and anaesthesia].

Authors:  S Rasche; T Koch; M Hübler
Journal:  Anaesthesist       Date:  2006-03       Impact factor: 1.041

5.  Drugs to be avoided in patients with long QT syndrome: Focus on the anaesthesiological management.

Authors:  Giovanni Fazio; Federica Vernuccio; Giuseppe Grutta; Giuseppe Lo Re
Journal:  World J Cardiol       Date:  2013-04-26

6.  Effects of High-Dose Rocuronium on the QTc Interval During Anaesthesia Induction in Patients Undergoing Coronary Artery Bypass Graft Surgery.

Authors:  Doğuş Ağdanlı; Tülün Öztürk; Ozan Ütük; Gönül Tezcan Keleş
Journal:  Turk J Anaesthesiol Reanim       Date:  2014-07-09

7.  Propofol-associated QTc prolongation.

Authors:  Michael J Scalese; Holly R Herring; R Chris Rathbun; Grant H Skrepnek; Toni L Ripley
Journal:  Ther Adv Drug Saf       Date:  2016-04-01

8.  Pharmacogenomics of anesthetic drugs in transgenic LQT1 and LQT2 rabbits reveal genotype-specific differential effects on cardiac repolarization.

Authors:  Katja E Odening; Omar Hyder; Leonard Chaves; Lorraine Schofield; Michael Brunner; Malcolm Kirk; Manfred Zehender; Xuwen Peng; Gideon Koren
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-03       Impact factor: 4.733

9.  [Perioperative treatment of patients with long QT syndrome].

Authors:  T Krönauer; P Friederich
Journal:  Anaesthesist       Date:  2015-08       Impact factor: 1.041

10.  Perioperative management of a patient with Rett syndrome.

Authors:  Hiromi Kako; David P Martin; Richard Cartabuke; Allan Beebe; Jan Klamar; Joseph D Tobias
Journal:  Int J Clin Exp Med       Date:  2013-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.